Clinical director [h1.location_city]
[job_alerts.create_a_job]
Clinical director • thornton co
- [promoted]
Executive Director, Global Clinical Development Program Lead
Denver StaffingDenver, CO, US- [promoted]
- [new]
Clinical Director - BCBA
Success On The Spectrum CentennialDenver, CO, US- [promoted]
- [new]
Director, Clinical Scientist, Respiratory (Denver)
ConfidentialDenver, CO, US- [promoted]
Associate Director, Clinical Account Manager
Capital RxDenver, CO, United StatesBCBA Clinical Director
Action Behavior CentersWheat Ridge, Colorado, USA- [promoted]
Associate Director, Clinical Account Manager
Judi HealthDenver, CO, USArea Director of Clinical Operations
Team Select Home CareDenver, Colorado, USA- [promoted]
- [new]
Clinical Pharmacology Director
VirtualVocationsDenver, Colorado, United States- [promoted]
Pathology Anatomic and Clinical Medical Director
HCA HealthcareDenver, CO, USSenior Director, Clinical Affairs
ConMedDenver, ColoradoClinical Instructor Nutrition & DPD Program Director
East Texas A&M UniversityCommerce, Colorado, USA- [promoted]
Associate Clinical Director (BCBA Required)
IntercareDenver, CO, US- [promoted]
Hospice Director of Clinical Operations
Three Oaks HospiceArvada, CO, USClinical Director | Boulder Programs
Clinica Family HealthLafayette, Colorado, US- [promoted]
Nurse Practitioner / Clinical Director - Men's Health Clinic
GAMEDAY MEN'S HEALTH THORNTONDenver, CO, US- [promoted]
Clinical Director
FRSearch PartnersDenver, CO, USSenior Director, Clinical Affairs
CONMED CorporationDenver, Colorado, USAClinical Director FT
USPIDenver, Colorado- [promoted]
Director Of Clinical Practice (Hospice)
BrightSpring Health ServicesDenver, CO, USExecutive Director, Global Clinical Development Program Lead
Denver StaffingDenver, CO, US- [job_card.full_time]
Global Clinical Development Program Leader
Within Otsuka Pharmaceutical Co. exists Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) a U.S.A. subsidiary exists the Global Clinical Development (GCD) department. OPDC-GCD are a group of physicians and scientists who lead clinical development activities for Otsuka's global health-care products. The Global Clinical Development Program Leader is responsible for leading the end-to-end strategy, and development and delivery of a portfolio of novel serotonergic agonists (NSA). Shaping and executing late-stage clinical development strategies for the NSA portfolio of therapeutic assets, ensuring programs progress efficiently toward registration and commercialization. This role serves as the primary and single point of contact for internal and external stakeholders, ensuring seamless integration, governance, and lifecycle management from early-stage development through submission to global health authorities. This role provides scientific, clinical, and strategic leadership across Phase II / III program design, evidence-generation plans, regulatory interactions, and cross-functional integration to support differentiated therapeutic value and patient outcomes. In addition to overseeing clinical development, the leader will play a central role in creating a unique, patient-centered go-to-market strategy tailored to the emerging psychedelic medicines landscape. This includes orchestrating health economics and outcomes research, defining care-delivery models, navigating reimbursement and market access pathways, and partnering with commercial, medical affairs, and external stakeholders to build scalable, ethically grounded treatment ecosystems.
The specific duties assigned to the Executive Director; Global Clinical Development Program Lead will include the following :
Key Role Accountabilities : Summary of Global Clinical Development Program Lead for the NSA Portfolio include :
- Establish & continually evolve global portfolio strategy indications / sequencing. Align with Product Development Committee (PDC) and the Early Development Team (EDT) based on internal strategy and competitive landscape
- Recommend individual asset strategies that supports a differentiated product profile including proposed go / no-go criteria (early to late phase)
- Broader portfolio evidence generation strategy
- Align COA endpoint development and validation work across individual assets
- Drive portfolio-wide stakeholder strategy through external landscape & policy shaping (GA, PASM, GMA, GRA, Corporate Comms) and identify synergies with the broader CNS portfolio
- Drive internal and external communication strategy
- Develop and continually evolve differentiated global go-to-market strategy based on unique attributes of assets within the portfolio :
- Reimbursement and coding coverage
- Broader portfolio global commercialization assessment / planning to drive asset's global CDP
- Patient support / wrap around services
- Provide overall portfolio asset prioritization and support for discovery programs and indication selection
- Set overarching regulatory strategy and endorse individual asset strategies as needed
- Endorse proposed go / no-go criteria and support PDC for action points and EDTs for governance engagement for portfolio assets
- Endorse CDPs for discovery / early stage and late-stage programs
- Portfolio KOL engagement & patient advocacy strategy
Strategy & Execution :
Leadership & Matrix Management :
Stakeholder Engagement & Communication :
Competencies :
Compensation :